Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody-Reference-Cited by-同舟云学术

Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody

Published:2017-03-20 Issue:5 Volume:38 Page:710-718
ISSN:1671-4083
Container-title:Acta Pharmacologica Sinica
language:en
Short-container-title:Acta Pharmacol Sin

Author:

Fu Jie,Wang Fang,Dong Li-hou,Zhang Jing,Deng Cheng-lian,Wang Xue-li,Xie Xin-yao,Zhang Jing,Deng Ruo-xian,Zhang Li-bo,Wu Hai,Feng Hui,Chen Bo,Song Hai-feng

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://www.nature.com/articles/aps2016161.pdf

Reference13 articles.

1. McDermott DF, Atkins MB . PD-1 as a potential target in cancer therapy. Cancer Med 2013; 2: 662–73.

2. Velu V, Titanji K, Zhu B, Husain S, Pladevega A, Lai L, et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009; 458: 206–10.

3. Fuller MJ, Callendret B, Zhu B, Freeman GJ, Hasselschwert DL, Satterfield W, et al. Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proc Natl Acad Sci U S A 2013; 110: 15001–6.

4. Richter C, Thieme S, Bandoła J, Laugsch M, Anastassiadis K, Brenner S . Generation of inducible immortalized dendritic cells with proper immune function in vitro and in vivo. PLoS One 2013; 8: e62621.

5. Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015; 16: 257–65.

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Navigating the landscape of PD-1/PD-L1 imaging tracers: from challenges to opportunities;Frontiers in Medicine;2024-06-07

2. Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial;Journal for ImmunoTherapy of Cancer;2024-06

3. Structure and function of therapeutic antibodies approved by the US FDA in 2023;Antibody Therapeutics;2024-03-19

4. Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study;Journal of Gastrointestinal Oncology;2023-04

5. Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study;Signal Transduction and Targeted Therapy;2023-03-17